GlassScriptPhysician profile
Smitha A Gubbi
NPI 1275620650
$6,634.64
in general payments reported to CMS, 2019-2025
41 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2020: $151 · 2022: $615 · 2023: $1,136 · 2024: $1,758 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,120.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $695.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.10 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $333.87 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $289.66 | 2024-2025 | |
| Lilly USA, LLC | $282.32 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $279.40 | 2019-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $276.46 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.26 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $247.81 | 2019-2025 | |
| Astellas Pharma US INC | $240.45 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $203.12 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Glaxosmithkline, LLC. | $196.89 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $180.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $143.53 | 2019-2025 | Lagevrio, Verquvo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $129.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $116.13 | 2019-2023 | |
| Abbott Laboratories | $110.34 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Almatica Pharma LLC | $101.48 | 2023-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Abbvie INC. | $79.67 | 2022-2025 | |
| Eisai INC. | $75.39 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $74.57 | 2023-2024 | Quviviq |
| Dexcom, INC. | $73.32 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.90 | 2022-2025 | Caplyta |
| Azurity Pharmaceuticals, INC. | $67.75 | 2024-2025 | Horizant, Edarbi |
| Route 92 Medical, INC. | $53.51 | 2022 | |
| Amgen INC. | $44.84 | 2023-2025 | Evenity, Prolia, Prolia |
| Amarin Pharma, INC. | $44.70 | 2019-2022 | |
| Aerin Medical INC. | $43.29 | 2024 | |
| Lundbeck LLC | $43.00 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $41.66 | 2019 | |
| Alkermes, INC. | $37.68 | 2023 | Aristada, Lybalvi |
| Daiichi Sankyo INC. | $34.96 | 2022-2025 | Injectafer |
| Horizon Therapeutics Plc | $29.99 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $25.74 | 2022-2025 | Gvoke Hypopen |
| Medtronic, INC. | $24.26 | 2024 | Intellis Adaptivestim |
| Depuy Synthes Sales INC. | $17.40 | 2023 | Monovisc, Orthovisc |
| Ibsa Pharma INC. | $17.39 | 2024 | Tirosint, Licart |
| Tanabe Pharma America, INC. | $15.50 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Gubbi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.